Chimera Bioengineering acquired by Vaxanix in May of 2024. Chimera is a biotherapeutics company focused on building RNA based gene regulatory systems for chimeric antigen receptor (CAR) T cell therapeutics with greater efficacy against solid tumors and superior safety.